Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors), RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesNervous System Diseases+ [2]

Active Indication

Skin and skin structure infectionsProsthetic joint infectionDiabetic foot infection

Inactive Indication

Duodenal ulcer caused by Helicobacter pyloriGram-Positive Bacterial InfectionsHelicobacter pylori infection+ [5]

Originator Organization

Cumbre Pharmaceuticals, Inc.

TenNor Therapeutics Suzhou Ltd.

Active Organization

Dan Nuo Yi Yao （ Zhong Shan ） You Xian Gong Si

TenNor Therapeutics Suzhou Ltd.University of Iowa Pharmaceuticals

Inactive Organization

Cumbre Pharmaceuticals, Inc.

Drug Highest PhasePhase 3

First Approval Date-

RegulationFast Track (United States), Orphan Drug (United States), Qualified Infectious Disease Product (United States), Special Review Project (China), Priority Review (United States)

Structure/Sequence

Molecular FormulaC65H81FN6O15

InChIKeyOPZFMLLAJBIKAN-UHFFFAOYSA-N

CAS Registry922717-97-3

Clinical Trials associated with Rifaquizinone

NCT06889701

/ Not yet recruitingPhase 1/2

A Phase 1/2, Randomized, Controlled, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 Administered Via Intra-articular Injection (IA) in Adult Participants With Early or Acute Hematogenous Prosthetic Joint Infection (PJI) Requiring or Not Requiring Debridement, Antibiotics, and Implants Retention (DAIR) After Total Knee Arthroplasty (TKA)

This is a Phase 1/2, randomized, controlled, open-label, proof-of-concept study to evaluate the safety and tolerability, local and systemic PK profiles of TNP-2092 administered IA on the basis of vancomycin IV and oral antibiotics therapy in participants with early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requiring or not requiring DAIR therapy after TKA.

Start Date01 Mar 2025

Sponsor / Collaborator

TenNor Therapeutics Suzhou Ltd.

[+1]

CTR20221320

/ CompletedPhase 1

评价注射用TNP-2092单剂给药、多剂连续静脉输注给药在中国健康受试者中的安全性、耐受性和药代动力学特征的单中心、随机、双盲、安慰剂对照、剂量递增I期临床试验

[Translation] A single-center, randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of single-dose and multiple-dose continuous intravenous infusion of TNP-2092 for injection in healthy Chinese subjects

评价注射用TNP-2092在中国健康受试者中单剂、多剂连续静脉输注给药的安全性和耐受性；评价注射用TNP-2092在中国健康受试者中单剂、多剂连续静脉输注给药的药代动力学特征。

[Translation]

To evaluate the safety and tolerability of TNP-2092 for injection as a single dose or multiple doses of continuous intravenous infusion in healthy Chinese subjects; To evaluate the pharmacokinetic characteristics of TNP-2092 for injection as a single dose or multiple doses of continuous intravenous infusion in healthy Chinese subjects.

Start Date07 Jul 2022

Sponsor / Collaborator

University of Iowa Pharmaceuticals

[+1]

NCT06394518

/ CompletedPhase 1

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.

Start Date07 Jul 2022

Sponsor / Collaborator

TenNor Therapeutics Suzhou Ltd.

100 Clinical Results associated with Rifaquizinone

100 Translational Medicine associated with Rifaquizinone

100 Patents (Medical) associated with Rifaquizinone

Literatures (Medical) associated with Rifaquizinone

14 Jun 2024·The Journal of infectious diseases

The Efficacy and Safety of an Intra-articular Dual-Acting Antibacterial Agent (TNP-2092) for Implant Infection–Associated Methicillin-Resistant Staphylococcus aureus

Article

Author: Dai, Tianyu ; Wang, Huan ; Zhang, Fan ; Wen, Yinxian ; Chen, Liaobin ; Ma, Chi ; Wang, Hui ; Ma, Zhenkun

Abstract:

Owing to the presence of microbial biofilm on the implant, the eradication of biofilm-associated infections poses a challenge for antibiotic therapies. The study aimed to investigate the efficacy and safety of the novel antibiotic agent TNP-2092 in the context of implant infections. In vivo, rats with periprosthetic joint infection (PJI) treated with antibiotics showed an increase in body weight and decrease in swelling, temperature, and width of knee, compared with the control group. Meanwhile, inflammatory markers in synovium and serum were decreased in the TNP-2092 group, consistent with the pathological results. Moreover, TNP-2092 was effective in eliminating bacteria and disruption biofilm formation, and further alleviated the abnormal bone absorption and reactive bone changes around the prosthesis. In conclusion, intra-articular injection of TNP-2092 is safe and effective in treating knee PJI in a rat model. The study provides a foundation for the future utilization of TNP-2092 in the management of implant-related infections.

01 Aug 2020·Future microbiologyQ3 · BIOLOGY

Rifamycin Use for Treatment of Helicobacter Pylori Infection: A Review of Recent Data

Q3 · BIOLOGY

Review

Author: Boyanova, Lyudmila ; Markovska, Rumyana ; Kandilarov, Nayden ; Hadzhiyski, Petyo ; Mitov, Ivan

Helicobacter pylori eradication has become increasingly challenging. We focused on recent data about rifamycin resistance and rifamycin-containing regimens. Rifampin (rifampicin) resistance rates were <1–18.8% (often ≤7%), while those to rifabutin were 0–<4%. To detect rifabutin resistance by rifampin, 4 mg/l breakpoint was suggested. Eradication success by rifaximin-based regimens was disappointing (<62%), while that of rifabutin-containing regimens was 54.5–>96%, reaching >81% in four studies. Some newer rifamycin analogs like TNP-2092 need further investigation. Briefly, although rifabutin-based regimens carry a risk of adverse effects or increasing mycobacterial resistance, they may be a rational choice for some multidrug-resistant H. pylori strains and as a third-line eradication therapy. Bismuth addition to rifabutin-based therapy and combined rifabutin-containing capsules (Talicia) are promising treatment options.

01 Jul 2020·Diagnostic microbiology and infectious diseaseQ4 · MEDICINE

In vitro activity of TNP-2092 against periprosthetic joint infection–associated staphylococci

Q4 · MEDICINE

Article

Author: Schmidt-Malan, Suzannah M ; Ma, Zhenkun ; Patel, Robin ; He, Shijie ; Yuan, Ying ; Fisher, Cody R

Staphylococci are the most common causes of periprosthetic joint infection (PJI). TNP-2092 is an investigational hybrid drug composed of rifamycin and quinolizinone pharmacophores conjugated via a covalent linker. We determined minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum biofilm bactericidal concentration (MBBC) values of TNP-2092 against 80 PJI-associated Staphylococcus aureus and Staphylococcus epidermidis isolates compared to ciprofloxacin and rifampin alone and in combination, alongside daptomycin and vancomycin. TNP-2092 exhibited the following activity against S. aureus: MIC₅₀/MIC_90, ≤0.0075/0.015 μg/mL; MBC₅₀/MBC₉₀, 0.5/4 μg/mL; and MBBC₅₀/MBBC₉₀, 0.5/2 μg/mL, and the following activity against S. epidermidis: MIC₅₀/MIC₉₀, ≤0.0075/0.015 μg/mL; MBC₅₀/MBC₉₀, 0.015/0.125 μg/mL; and MBBC₅₀/MBBC₉₀, 0.06/0.25 μg/mL. TNP-2092 MIC, MBC, and MBBC values were >8 μg/mL for 1 isolate, while MIC values were ≤0.25 μg/mL and MBC and MBBC values were ≤4 μg/mL for all other isolates. Results of this study show that TNP-2092 has promising in vitro activity against PJI-associated staphylococci.

News (Medical) associated with Rifaquizinone

16 Oct 2024

·www.prnewswire.com

TenNor Announces More than 300 Million RMB Financing to Support Development and Commercialization of Late-Stage Assets Including Rifasutenizol for Heliobacter pylori Infections

SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing round for more than 300 million RMB. New investor AMR Action Fund joined Zhongshan Venture Capital and other existing investors in the round. The proceeds will be used to support the development and to seek regulatory approval in China of rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. "We are extremely glad to have the financial support from AMR Action Fund, Zhongshan Venture Capital, and other existing investors," said Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics. "TenNor is dedicated to addressing the challenges of drug-resistant infections in China and around the world by innovating solutions for diseases currently without adequate therapies. With the additional funding, TenNor is well positioned to seek regulatory approval and bring to market rifasutenizol, a novel therapy for Helicobacter pylori infections, while also advancing a second product that will target prosthetic joint infections and similar infections associated with medical devices." "The global burden of drug-resistant bacterial infections is staggering and only getting worse, with recent data in The Lancet indicating that nearly 40 million people will die from antimicrobial resistance by 2050," said AMR Action Fund Chief Executive Officer Henry Skinnner, PhD. "We are pleased to support the team at TenNor as they advance the development of novel antibiotics that could save the lives of patients around the world and significantly reduce the suffering associated with these intractable infections." "TenNor is a leading company with multiple assets in late-stage of clinical development for the treatment of diseases associated with bacterial infections and metabolism," said Cheng Zhang, Chairman of Zhongshan Venture Capital, "TenNor adopts a first-line strategy to address major unmet needs in China. The products TenNor is developing has significant market potential in China and around the world. We are very glad to support this round of investment together with AMR Action Fund, a global leader in the antimicrobial space." TenNor develops differentiated products for diseases associated with bacterial infections and metabolism that currently lack adequate therapeutic options. The company adopts a business strategy to develop first-line therapies for indications with clear unmet medical needs and major market potential to ensure commercial success. TNP-2198 (rifasutenizol) is a novel multi-targeting drug candidate with a synergistic mechanism of action against anaerobic and microaerophile bacteria. It has potential to become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. TNP-2198 could play an important role in supporting the large-scale screening-and-eradication strategy to prevent gastric cancers in regions with high gastric cancer rate. TenNor is completing a phase 3 clinical trial of TNP-2198 in China and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA). TNP-2092 (rifaquizinone) is a novel triple targeting drug candidate designed to address the dual challenges of antimicrobial resistance and persistence associated with medical device infections. TenNor has completed six phase 1 and phase 2 clinical trials for TNP-2092 for injection and is planning for a phase 3 multiregional clinical trial for the treatment of prosthetic joint infections. TNP-2092 has received QIDP, Fast Track and Orphan Drug designations from the U.S. FDA. About TenNor Therapeutics TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products against diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development portfolio with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world. For more information please visit: . SOURCE TenNor Therapeutics (Suzhou) Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Fast TrackQualified Infectious Disease ProductOrphan DrugPhase 2Phase 3

27 Feb 2024

·www.businesswire.com

Helicobacter Pylori Infection Pipeline Insight Report 2024: Insights About 5+ Companies and 5+ Pipeline Drugs Featuring TenNor Therapeutics, Servatus Biopharmaceuticals, and TenNor Therapeutics - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Helicobacter Pylori Infection - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Helicobacter Pylori Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Helicobacter Pylori Infection R&D. The therapies under development are focused on novel approaches to treat/improve Helicobacter Pylori Infection. Helicobacter Pylori Infection Emerging Drugs Chapters This segment of the Helicobacter Pylori Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Helicobacter Pylori Infection Emerging Drugs TNP-2198: TenNor Therapeutics (Suzhou) Limited Rifasutenizole (TNP-2198) is a new molecule entity discovered and developed by TenNor specifically for the treatment of H. pylori infection. Its multi-targeting synergistic mechanism delivers low drug resistance frequencies, maintaining excellent bactericidal activities against H. pylori strains isolated from various regions. Rifasutenizole has the potential to streamline the eradication regimes of H. pylori so as to improve the compliance and enable a seamless connection to the urea breath test (UBT), rendering the possibility of carrying out screening-eradication on large scale. TenNor is currently conducting a multi-center, randomized, double-blind, bismuth-containing quadruple therapy-controlled Phase III study to evaluate the efficacy and safety of Rifasutenizole in the primary treatment of patients with H. pylori infection. SVT1C4610: Servatus Biopharmaceuticals SVT1C4610 is a live biotherapeutic type of drug. Its mechanism include Bacteria replacements, gastrointestinal microbiome modulators. Its main therapeutic area is infectious disease control. Currently, the drug is in phase I stage of its clinical trial for the treatment of H. pylori infection. Major Players in Helicobacter Pylori Infection There are approx. 5+ key companies which are developing the therapies for Helicobacter Pylori Infection. The companies which have their Helicobacter Pylori Infection drug candidates in the most advanced stage, i.e. Phase III include, TenNor Therapeutics (Suzhou) Limited. Helicobacter Pylori Infection: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Helicobacter Pylori Infection therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Helicobacter Pylori Infection drugs. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type Helicobacter Pylori Infection Report Insights Helicobacter Pylori Infection Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Helicobacter Pylori Infection Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Players TenNor Therapeutics (Suzhou) Limited Servatus Biopharmaceuticals TenNor Therapeutics Inc. Key Products TNP-2198 SVT-1C4610 TNP-2092 For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ck4nzd About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Phase 3Phase 1Phase 2Gene Therapy

23 Nov 2023

·www.prnewswire.com

Prosthetic Joint Infections Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5 Drugs

DUBLIN, Nov. 23, 2023 /PRNewswire/ -- The "Prosthetic joint infections - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Prosthetic joint infections- Pipeline Insight, 2023" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prosthetic joint infections pipeline landscape is provided which includes the disease overview and Prosthetic joint infections treatment guidelines. The assessment part of the report embraces, in depth Prosthetic joint infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prosthetic joint infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infections R&D. The therapies under development are focused on novel approaches to treat/improve Prosthetic joint infections. Prosthetic joint infections Emerging Drugs Chapters This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Prosthetic joint infections Emerging Drugs TNP 2092: TenNor Therapeutics TNP-2092 is a multi-targeting drug conjugate that exerts antibacterial activity by inhibiting three essential targets in bacterial biofilms: RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has demonstrated strong bactericidal activity, a low frequency for the development of resistance, and an excellent safety profile. The drug is in Phase II clinical developmental studies for the treatment of bacterial infections and skin and soft tissue infections. In January 2020, TenNor Therapeutics received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections. PLG0206: Peptilogics PLG0206 is an intravenous antibiotic derived from the cationic antibiotic peptide (eCAP) platform. PLG0206 works by targeting and disrupting bacterial membranes leading to the death of bacterial cells. PLG0206 has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for the treatment of prosthetic joint infections (PJI). Currently, the drug is in the Phase I stage of its development for the treatment of PJI. Prosthetic joint infections: Therapeutic Assessment This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Prosthetic joint infections There are approx. 5+ key companies which are developing the therapies for Prosthetic joint infections. The companies which have their Prosthetic joint infections drug candidates in the most advanced stage, i.e. phase II include, TenNor Therapeutics. Prosthetic joint infections: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs. Key Questions Answered How many companies are developing Prosthetic joint infections drugs? How many Prosthetic joint infections drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prosthetic joint infections? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infections therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Prosthetic joint infections and their status? What are the key designations that have been granted to the emerging drugs? Key Players Adaptive Phage Therapeutics TenNor Therapeutics Peptilogics Key Products Bacteriophage TNP 2092 PLG0206 Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type Prosthetic joint infections Report Insights Prosthetic joint infections Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Prosthetic joint infections Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Orphan DrugPhase 2Phase 1Clinical ResultQualified Infectious Disease Product

100 Deals associated with Rifaquizinone

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16312

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Skin and skin structure infections	Phase 3	China	TenNor Therapeutics Suzhou Ltd.	26 Feb 2022
Prosthetic joint infection	Phase 2	China	TenNor Therapeutics Suzhou Ltd.	05 Mar 2025
Prosthetic joint infection	Phase 2	China	University of Iowa Pharmaceuticals	05 Mar 2025
Irritable bowel syndrome with diarrhea	Phase 2	China	TenNor Therapeutics Suzhou Ltd.	09 Sep 2021
Hyperammonemia	Phase 2	China	TenNor Therapeutics Suzhou Ltd.	27 Aug 2020
Liver Cirrhosis	Phase 2	China	TenNor Therapeutics Suzhou Ltd.	27 Aug 2020
Hepatic Encephalopathy	Phase 2	China	TenNor Therapeutics Suzhou Ltd.	25 Aug 2020
Gram-Positive Bacterial Infections	Phase 2	United States	TenNor Therapeutics Suzhou Ltd.	20 Apr 2019
Skin Diseases, Bacterial	Phase 2	United States	TenNor Therapeutics Suzhou Ltd.	20 Apr 2019
Helicobacter pylori infection	Phase 1	China	TenNor Therapeutics Suzhou Ltd.	02 Nov 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06190340 (CTgov)	Phase 1	Helicobacter pylori infection	40	TNP-2092 capsules (TNP-2092 Capsules 100 mg)	vsquboblve = vzssgfcalp braznpwfov (nafkawevoi, svohaphgaq - ykzyaduxht) View more	-	29 Jan 2025
				TNP-2092 capsules (TNP-2092 Capsules 300 mg)	vsquboblve = kuolqzfhgv braznpwfov (nafkawevoi, lelibhcheh - ulniqbkzqu) View more
NCT03964493 (P2_ABSSSI, CTgov)	Phase 2	Skin Diseases, Bacterial \| Gram-Positive Bacterial Infections \| Skin and skin structure infections	120	TNP-2092 (TNP-2092)	pfxcfhppzl = jscaesyjxb siivlqeynd (gltarajzqg, hqwqqjtjzo - smprubbvvg) View more	-	01 Dec 2023
				Vancomycin (Vancomycin)	pfxcfhppzl = fdwjvmwivc siivlqeynd (gltarajzqg, guntlyyoak - nzovacorja) View more
NCT03964493 (P2_ABSSSI, Biospace) Manual	Phase 2	Skin and skin structure infections	-	TNP-2092	nbjjaznucs(sbkmqcrtkw) = jmuocdqjxa kzmotuqcso (hgqynakiew ) View more	Positive	11 Nov 2019
				vancomycin	nbjjaznucs(sbkmqcrtkw) = oewezkttww kzmotuqcso (hgqynakiew ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis